Completed

Retrovir Capsules for Psoriasis in HIV Positive Patients

Study Aim

This study aims to treat psoriasis in HIV positive patients using Retrovir Capsules.

What is being tested

Zidovudine

Drug

Who is being recruted

Blood-Borne Infections+17

+ Urogenital Diseases

+ Genital Diseases

Over 18 Years

+16 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Interventional

See protocol details

Summary

Principal SponsorGlaxo Wellcome

Last updated: June 24, 2005

Sourced from a government-validated database.Claim as a partner

This study explores the use of Retrovir (AZT) capsules in managing psoriasis in patients who are HIV antibody positive. Psoriasis is a skin condition, and Retrovir, a medication known for its effectiveness in treating AIDS, has shown potential in treating psoriasis as well. This research aims to find a suitable treatment for HIV positive patients with psoriasis, especially those whose condition progresses rapidly. The potential outcomes of this study could lead to improved care for this specific patient population. During the study, participants receive Retrovir capsules as part of their treatment regimen. The study's main focus is to evaluate the feasibility of using Retrovir for managing psoriasis in this group of patients. The effectiveness of the treatment is measured by observing changes in the patients' psoriasis symptoms. This study does not mention any specific risks or benefits associated with participation.

NCT00002286

Principal SponsorGlaxo Wellcome

Last updated: June 24, 2005

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSkin DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsSkin and Connective Tissue DiseasesSkin Diseases, PapulosquamousAcquired Immunodeficiency SyndromePsoriasisHIV Infections

Criteria

3 inclusion criteria required to participate

Allowed prior medication: Zidovudine (AZT)

Biopsy-proven psoriasis with 3 distinct psoriatic lesions. (Biopsy-proven Reiter's syndrome patients with 3 distinct cutaneous lesions may be included.)

Documented HIV antibody (by federally licensed ELISA test) positive patients

13 exclusion criteria prevent from participating

Impaired renal function

Known hypersensitivity to zidovudine (AZT)

Presence of any AIDS-defining neoplasms (excluding Kaposi's sarcoma) such as central nervous system (CNS) lymphoma

Presence of any active opportunistic infection

Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Glaxo Wellcome Inc

Research Triangle Park, United StatesOpen Glaxo Wellcome Inc in Google Maps

CompletedOne Study Center